Invasive Aspergillosis

Treatment Results in Favorable Response

Published in TB and Outbreaks Week, October 3rd, 2000

Clinical study results showed that treatment with Cancidas (caspofungin acetate), an investigational medicine, resulted in a favorable response in 22 of 54 patients (41%) diagnosed with life-threatening invasive aspergillosis who were not responding to or were intolerant of other antifungal therapy.

For patients receiving more than seven days of therapy, the response rate was 49% (22 of 45). Cancidas is an echinocandin known as a glucan synthesis inhibitor that is being developed by Merck & Co., Inc. (MRK) to treat serious fungal infections in adults.

The study was presented at the 40th Annual Meeting of the Interscience Conference on Antimicrobial...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of TB and Outbreaks Week

Source: TB and Outbreaks Week (2000-10-03)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry